|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Fourth Quarter of 2009
Decision Resources, Inc., Jan 2010, Pages: 30
The fourth quarter of 2009 left drug manufacturers with many unanswered questions that will have a major bearing on the future direction of the pharmaceutical industry. The steady progress of healthcare reform legislation in the United States was thrown into disarray by defeat for the Democrats in a Senate special election in Massachusetts. European governments struggled to find new ways to strike a balance between containing costs and promoting access to innovative medicines. The Japanese government prepared for scheduled price revisions in April 2010 while continuing to evaluate an industry proposal for reform of the pricing and reimbursement system.
Questions Answered in This Report:
- In the United States, an unexpected electoral setback for the Democrats threatens to derail the passage of legislation that would bring about the most radical transformation of the U.S. healthcare system since the introduction of Medicare and Medicaid in 1965.
What are the key similarities and differences between the bills drafted by the Senate and the House of Representatives? What contributions are likely to be expected from the pharmaceutical industry, and why have drug manufacturers been criticized for their recent pricing policies? What are the potential repercussions of the election result?
- European governments continue to focus on reference pricing and boosting the use of generics to contain pharmaceutical expenditures.
What are the prospective changes for the German and Spanish reference pricing systems? How do the French and U.K. governments intend to stimulate greater use of generics?
- The German pharmaceutical market faces the prospect of significant changes in the near future.
What are the healthcare priorities of the new German government? What is the outlook for health technology assessment in Germany? What question has been raised with regard to rebate contracts?
- The United Kingdom has gone from being one of the highest-priced pharmaceutical markets in Europe to the lowest-priced market in Europe.
What are the reasons for this dramatic change? How has the decline of U.K. prices relative to prices in other European markets influenced parallel trade patterns and affected pharmaceutical supply in the United Kingdom?
- Japan is scheduled to conduct its next biennial price revision in April 2010. What is the likely level of average price cuts? How will price cuts for long-listed drugs, a new price premium for the development of new drugs, and elimination of off-label drug use impact the Japanese pharmaceutical industry?
Scope:
- Issues affecting the pharmaceutical industry in the United States: healthcare reform; price increases; healthcare expenditure trends.
- Issues affecting the pharmaceutical industry in Europe: changes in German healthcare policy; new cost-containment strategy in France; modifications to the German and Spanish reference pricing systems; initiatives to stimulate greater use of generics in France and the United Kingdom; outlook for health economic evaluation in Germany.
- Issues affecting the pharmaceutical industry in Japan: results of the most recent review of Japanese prices in preparation for the next biennial price revision in April 2010; prospects for price maintenance system proposed by the pharmaceutical industry.
Customers who bought this item also bought
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Pharmaceutical Pricing, Reimbursement and Market Access News in the First Quarter of 2010
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Second Quarter of 2011
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
The Pricing and Reimbursement Environment for Respiratory Disease Therapies
Specialty Generics: Climbing the value chain
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009
Generic Pharmaceuticals Market – A Global Analysis
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Fourth Quarter of 2010
|
|
|
|
